Encouraging results noted for pancreatitis patients with exocrine pancreatic insufficiency Early data shows favorable safety profile, positive dose tolerance Favorable trends observed in other identified markers Study is being performed at four sites in Australia and New Zealand New York-based AzurRx BioPharma Inc. (NASDAQ: AZRX), a biopharmaceutical company engaged in the research and development of … Continue reading “AzurRx BioPharma, Inc. (NASDAQ: AZRX) Announces Encouraging Results in Phase IIa Trial for MS1819-SD”
Early data from the first EPI patients enrolled in clinical studies utilizing AzurRx’s MS1819 therapy shows positive results Data indicates that MS1819, a recombinant lipase derived from the yeast Yarrowia Lipolytica, is showing a favorable safety profile and encouraging signs of efficacy and drug tolerance The study is being performed at four sites in Australia … Continue reading “AzurRx BioPharma, Inc. (NASDAQ: AZRX) Adds 6th Patient to MS1819 Phase II Clinical Trial”
AzurRx BioPharma (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, … Continue reading “AzurRx BioPharma, Inc. (NASDAQ: AZRX) Starts Presentation at the 2017 Marcum Microcap Conference”
With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ: AZRX) core science team is the real strength behind the company’s developing portfolio of recombinant therapies. AzurRx … Continue reading “AzurRx BioPharma, Inc. (NASDAQ: AZRX) is “One to Watch””
AzurRx BioPharma (NASDAQ: AZRX) this morning announced the closing of a $5 million private placement that the company says will fund the continuation of its lead development program. “We are very grateful for the continued support of our investors and thrilled that the financing was over-subscribed,” AzurRx president and CEO Thijs Spoor stated in the … Continue reading “NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Raises $5M in Private Placement; Proceeds will Fund Continued Development of Lead Candidate”
Exocrine Pancreatic Insufficiency, or EPI, is a problem in a person’s digestive system. Simply put, EPI is when the pancreas cannot produce enough of the enzymes that the body requires to break down and absorb nutrients. Unfortunately, this means that the body is unable to absorb the right fats and nutrients, often leading to weight … Continue reading “AzurRx BioPharma, Inc. (NASDAQ: AZRX) Overcoming Current Exocrine Pancreatic Insufficiency Treatment Limitations”
